- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04513509
Rate Control in Patients With Atrial Fibrillation (RaP-AF)
August 16, 2020 updated by: National Taiwan University Hospital
The Surrogate Marker of Rate Control in Patients With Atrial Fibrillation
To search for the best marker for the patients in atrial fibrillation with rate control
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
In an aging society, the prevalence of atrial fibrillation is increasing.
The main treatment strategy is to reduce the complications of embolic stroke and heart failure.
Among these patients, a group of them will choose to have "rate control" based on the heart conditions and the preference of the patients.
The strategy is to control the ventricular rate by drugs to prevent the heart from failure.
However, when the physicians attempt to do so, they encounter two questions: how much is the optimal drug dose?
And what is the best marker we are looking to?
To answer these questions, the investigators design a prospective, cross-over study to explore this issue.
The participants will do cardiopulmonary exercise test (CPET) before and after treatment.
They will receive another CPET if drug dose is titrated up.
With the study, the investigators will understand whether a resting heart rate can be a good marker for optimal drug dosage, and what is the optimal range of heart rate the physicians should target.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chih-Chieh Yu, MD.PhD
- Phone Number: 65257 +886-2-23123456
- Email: sweetchieh@gmail.com
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Contact:
- Chih-Chieh Yu, MD.PhD.
- Phone Number: 65257 886-2-23123456
- Email: sweetchieh@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 20~90 years old
- Rate control is preferred after shared decision making
Exclusion Criteria:
- cannot cooperate with or complete CPET
- has contraindication for CPET, such as uncontrolled heart failure, hypertension, angina, valvular heart disease, lung function impariment that SaO2<90% at room air.
- Ventricular rate below 80/min before any medication
- Permanent pacemaker implanted
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rate control
|
Start with empirical lower dose for 3 months, and then titrate up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Maximal Oxygen consumption
Time Frame: 0, 3, 6 months
|
acquire the data by Cardiopulmonary exercise test (CPET) with different (low and high) drug dosages for rate control
|
0, 3, 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 7, 2020
Primary Completion (Anticipated)
June 30, 2022
Study Completion (Anticipated)
June 30, 2022
Study Registration Dates
First Submitted
August 9, 2020
First Submitted That Met QC Criteria
August 12, 2020
First Posted (Actual)
August 14, 2020
Study Record Updates
Last Update Posted (Actual)
August 18, 2020
Last Update Submitted That Met QC Criteria
August 16, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Atrial Fibrillation
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Protective Agents
- Adrenergic Agonists
- Cardiotonic Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Adrenergic beta-Agonists
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta-1 Receptor Agonists
- Propranolol
- Digoxin
- Bisoprolol
- Nebivolol
- Metoprolol
- Verapamil
- Diltiazem
- Atenolol
Other Study ID Numbers
- 202006205RIND
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin
-
Weill Medical College of Cornell UniversityNational Institute on Aging (NIA)CompletedHeart Failure | Heart Disease | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction | Cardiac FailureUnited States
-
Weill Medical College of Cornell UniversityThe New York Community TrustCompletedHeart Failure | Heart Disease | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction | Cardiac FailureUnited States
-
Tehran University of Medical SciencesCompletedRapid Ventricular Response Atrial FibrillationIran, Islamic Republic of
-
University of UtahBoston University; University of Pennsylvania; Northwestern University; Columbia... and other collaboratorsCompleted